allergic rhinitis archivos - Page 7 of 7

Mar 25

Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement

By Bilastina Selected articles

Hellings PW, Pugin B, Mariën G, Bachert C, Breynaert C, et al.

Physicians dealing with Allergic rhinitis (AR) patients should inform patients on tolerance-inducing effects of Allergen immunotherapy (AIT) and are in the need of a harmonized and practical guide that supports them in selecting eligible patients for AIT, in choosing evidence-based AIT products and in following treatment protocols with proven efficacy. Therefore, a stepwise and holistic approach is needed for better adoption of AIT in the real-life setting in Belgium.

This document is only available for registered healthcare professionals

Mar 01

Love0

Clinical and immunological differences between asymptomatic HDM-sensitized and HDM-allergic rhinitis patients

By Bilastina Selected articles

Zidarn M, Robič M, Krivec A, Šilar M, Resch-Marat Y, Vrtala S, Kopač P, Bajrović N, Valenta R, Korošec P.

Confirmation of the clinical relevance of sensitisation is important for the diagnosis of allergic rhinitis (AR).

This document is only available for registered healthcare professionals

Feb 12

Love0

Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties.

By Bilastina Articles about Bilastine

Kawauchi H, Yanai K, Wang DY, Itahashi K, Okubo K.

Antihistamines targeting the histamine H₁ receptor play an important role in improving and maintaining the quality of life of patients with allergic rhinitis. For more effective and safer use of second-generation drugs, which are recommended by various guidelines, a classification based on their detailed characteristics is necessary. Antihistamines for first-line therapy should not have central depressant/sedative activities.
Among the non-sedating group, fexofenadine and bilastine are classified into “non-brain-penetrating antihistamines”.
This review summarizes that the non-brain-penetrating antihistamines should be chosen for the first-line therapy of mild allergic rhinitis.

This document is only available for registered healthcare professionals

Feb 11

Love0

Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients

By Bilastina Articles about Bilastine

Demonte A, Guanti MB, Liberati S, Biffi A, Fernando F, Fainello M, Pepe P

This study is the first done in patients with allergic rhinitis and/or chronic urticaria using a F1-high speed simulator-driving test evaluating subjects’ performance under bilastine treatment.

This document is only available for registered healthcare professionals

Feb 11

Love0

Estudio de bilastina en pacientes japoneses

One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases

By Bilastina Articles about Bilastine

Yagami A, Furue M, Togawa M, Saito A, Hide M.

A number of second-generation non-sedating antihistamines are used in clinical practices over the world. However, long-term safety and efficacy have not been proved high level evidence based medicine.
In conclusion, long-term treatment with bilastine 20 mg once daily for 52 weeks is safe and well tolerated in Japanese patients with hronic spontaneous urticaria (CSU) or pruritus associated with skin diseases. Bilastine improved disease symptoms of both conditions early in treatment, and the efficacy was maintained throughout the treatment.

This document is only available for registered healthcare professionals

Feb 11

Love0

Alergológica 2015: A National Survey on Allergic Diseases in the Spanish Pediatric Population

By Bilastina Selected articles

Ojeda P, Ibáñez MD, Olaguibel JM, Sastre J, Chivato T; investigators participating in the National Survey of the Spanish Society of Allergology and Clinical Immunology Alergológica 2015.

The findings of Alergológica 2015 show a notable increased frequency of allergic rhinitis, drug allergy, and food allergy. The frequency of other allergic conditions remained unchanged, except for asthma, whose frequency decreased, as in adult patients.

This document is only available for registered healthcare professionals

Feb 10

Love0

The relationship between IL-17A and IL-22 expression and clinical severity in patients with moderate/severe persistent allergic rhinitis

By Bilastina Selected articles

Shahsavan S, Pirayesh A, Samani OZ, Shirzad H, Zamani MA, Amani S, Kazemi SM, Moghni M, Deris F, Bageri N, Salimzadeh L, Tavakoli G, Arjenaki MG.

The aim of the present study was to investigate the levels of IL-22 and IL-17A in AR patients and their association with clinical severity of persistent allergic rhinitis (PAR).

This document is only available for registered healthcare professionals

Feb 10

Love0

Adherence to treatment in allergic rhinitis using mobile technology. the mask study

By Bilastina Selected articles

Menditto E, Costa E, Midão L, Bosnic-Anticevich S, Novellino E, Bialek S, Briedis V, Mair A, Rajabian-Soderlund R, Arnavielhe S, Bedbrook A, Czarlewski W, Annesi-Maesano I, Anto JM, Devillier P, De Vries G, Keil T, Sheikh A, Orlando V, Larenas-Linnemann D, Cecchi L, De Feo G, Illario M, Stellato C, Fonseca J, Malva J, Morais-Almeida M, Pereira AM, Todo-Bom A, Kvedariene V, Valiulis A, Bergmann KC, Klimek L, Mösges R, Pfaar O, Zuberbier T, Cardona V, Mullol J, Papadopoulos NG, Prokopakis EP, Bewick M, Ryan D, Roller-Wirnsberger RE, Tomazic PV, Cruz AA, Kuna P, Samolinski B, Fokkens WJ, Reitsma S, Bosse I, Fontaine JF, Laune D, Haahtela T, Toppila-Salmi S, Bachert C, Hellings PW, Melén E, Wickman M, Bindslev-Jensen C, Eller E, O’Hehir RE, Cingi C, Gemicioğlu B, Kalayci O, Ivancevich JC, Bousquet Jl MASK group.

Adherence to treatment is low in allergic rhinitis. This study shows an approach for measuring retrospective adherence based on a mobile app. This represent a novel approach also for analyzing medication taking behavior in a real-world setting.

This document is only available for registered healthcare professionals

Feb 10

Love0

rinitis alérgica y rinosinusitis crónica

Different effects of allergic rhinitis on nasal mucosa remodeling in chronic rhinosinusitis with and without nasal polyps

By Bilastina Selected articles

Xiang R, Zhang QP, Zhang W, Kong YG, Tan L, Chen SM, Deng YQ, Tao ZZ, Xu Y.

Allergic rhinitis (AR) has been reported to be associated with chronic rhinosinusitis (CRS). The objective of this study was to investigate the effect of AR on nasal mucosa remodeling in CRS. AR could enhance the remodeling process in CRS. Moreover, Allergic rhinitis had different effects on chronic rhinosinusitis with nasal polyps and CRS without nasal polyps.

Sólo profesionales sanitarios registrados pueden ver este documento

Acceder

Feb 10

Love0

Association of allergic rhinitis with obstructive sleep apnea: A meta-analysis

By Bilastina Selected articles

Cao Y, Wu S, Zhang L, Yang Y, Cao S, Li Q.

The prevalence of Allergic Rhinitis in OSA/SDB is considerably high and children with SDB suffering from a higher incidence of AR than non-SDB. OSA adults accompanied with AR do not have any influences on sleep parameters.
Allergic rhinitis (AR); obstructive sleep apnea (OSA); sleep-disordered breathing (SDB).

This document is only available for registered healthcare professionals

Feb 10

Love0

Relación entorno familiar enfermedades tempranas rinitis alérgica

Home environment and diseases in early life are associated with allergic rhinitis

By Bilastina Selected articles

Kang X, Tu H, Tian T, Huang Z, Luo L, Shen L, Ye J.

Risk factors in relation to allergic rhinitis (AR) remain unclear despite considerable interest. This study aimed to analysis the relationship between home environment and diseases in early life and AR.

This document is only available for registered healthcare professionals

Feb 10

Love0

Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study

By Bilastina Articles about Bilastine

Okubo K, Gotoh M, Asako M, Nomura Y, Togawa M, Saito A, Honda T, Ohashi Y.

After 2-week treatment period, bilastine 20 mg once daily was effective and tolerable in Japanese patients with perennial allergic rhinitis (PAR), and exhibited a rapid onset of action.

This document is only available for registered healthcare professionals

allergic rhinitis

Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement

Clinical and immunological differences between asymptomatic HDM-sensitized and HDM-allergic rhinitis patients

Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties.

Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients

One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases

Alergológica 2015: A National Survey on Allergic Diseases in the Spanish Pediatric Population

The relationship between IL-17A and IL-22 expression and clinical severity in patients with moderate/severe persistent allergic rhinitis

Adherence to treatment in allergic rhinitis using mobile technology. the mask study

Different effects of allergic rhinitis on nasal mucosa remodeling in chronic rhinosinusitis with and without nasal polyps

Association of allergic rhinitis with obstructive sleep apnea: A meta-analysis

Home environment and diseases in early life are associated with allergic rhinitis

Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study

Archives

MDIG0119INDEF0419